[3] EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2025[EB/OL]. [2025-03-23]. https://uroweb.org/guidelines/prostate-cancer. [4] FREEDLAND S J, DE GIORGI U, GLEAVE M, et al. A phase 3 randomis...
Radium 223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover and has demonstrated a survival benefit in metastatic prostate cancer, but its benefits as a monotherapy in BCR without ADT have not been explored prior to this study. This strategy may be ...
等老师在Molecular Cancer(IF=27.7)上,在线发表题为“Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells”的论文,此论文使用了联科生物Annexin V-APC/PI Apoptosis Kit细胞凋亡试剂盒(货号:AP107)...
Close Surgical Margins Hike Risk of BCRThe article reports on a study which discusses the close surgical margins associated with the increased risk of biochemical recurrence (BCR) among patients who underwent radica...
Dasatinib Inhibits Lung Cancer Cell Growth and Patient Derived Tumor Growth in Mice by Targeting LIMK1. Front Cell Dev Biol. 2020 Dec 4;8:556532.3.Ryu KY, et al. Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling. J ...
2024年10月28日,中国广东省广州市广州医科大学附属第一医院Chengwu Zeng, Yangqiu Li等老师在Molecular Cancer(IF=27.7)上,在线发表题为“Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells”的论文,此论文使用了联科生物Annexin V-APC/PI ...
Chronic Myeloid Leukaemia (CML) is caused by the BCR/ABL1 fusion gene. Both the presence and the levels of BCR/ABL1 expression seem to be critical for CML progression from chronic phase (CP) to blast crisis (BC). After the oncogenic translocation, the BC
Imatinib is highly effective in the treatment of chronic myelogenous leukemia (CML), but the primary and acquired imatinib resistance remains the big hurdle. Molecular mechanisms for CML resistance to tyrosine kinase inhibitors, beyond point mutations in
Dynamic monitoring of liver and spleen stiffnesses or in combination with bone marrow examination in future can help evaluate the condition of patients with BCR-ABL-negative myeloproliferative neoplasms. KEYWORDS: Myeloproliferative disorders;Liver;Spleen;Fibroscan;Liver Stiffness Measurement;Spleen Stiffness ...
STI-571 (Figure 6, see above)134,135 illustrates the first successful development of small-molecule inhibitor of Bcr-Abl kinase to advance into clinical testing and the first-in-class compound approved in the USA for the treatment of CML (and an increasing number of other cancer indi...